Why the hold-up?
It a good chance it centres around the future of the other drug in the NEU portfolio - potential partners don't want to be upstaged down the track.
Neuren’s second patented drug candidate, NNZ-2591, is a synthetic analogue of a naturally occurring neuropeptide, which has been shown to have neuroprotective and nootropic (memory enhancing) effects in multiple animal models. NNZ-2591 has shown encouraging results in wellvalidated preclinical models of cognitive impairment, Fragile X syndrome, traumatic brain injury, stroke, Parkinson’s disease, peripheral neuropathy and multiple sclerosis.
- Forums
- ASX - By Stock
- wtf?
Why the hold-up? It a good chance it centres around the future...
-
- There are more pages in this discussion • 68 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
|
|||||
Last
$20.47 |
Change
0.610(3.07%) |
Mkt cap ! $2.583B |
Open | High | Low | Value | Volume |
$20.00 | $20.49 | $19.94 | $2.551M | 126.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 66 | $20.46 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$20.48 | 1155 | 6 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
7 | 117 | 20.320 |
5 | 97 | 20.310 |
7 | 277 | 20.300 |
4 | 219 | 20.290 |
6 | 227 | 20.280 |
Price($) | Vol. | No. |
---|---|---|
20.340 | 184 | 7 |
20.350 | 635 | 7 |
20.360 | 186 | 2 |
20.370 | 276 | 3 |
20.380 | 456 | 3 |
Last trade - 11.55am 12/07/2024 (20 minute delay) ? |
Featured News
TLX
Telix jumps 11.6% as US government indicates proposed medicare changes won't affect prostate cancer drug
RNU
Renascor wins a funding boost given it wants to produce a critical mineral – but $5M award pales in comparison to some
NEU (ASX) Chart |